Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

European Journal of Pharmacology

Volumn 584, Issue 1, 2008, Pages 118-124

  Zheng, Shuqin ^a   Hoos, Lizbeth ^a   Cook, John ^a   Tetzloff, Glen ^a   Davis Jr , Harry ^a   van Heek, Margaret ^a   Hwa, Joyce J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alanine aminotransferase; Cholesterol; Fibrosis and steatohepatitis; Steatosis; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; EZETIMIBE; FAT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG DOSE COMPARISON; HEPATOMEGALY; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID DIET; LIVER FIBROSIS; LIVER PROTECTION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL ESTERS; CHOLESTEROL, DIETARY; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HEPATOMEGALY; LIVER; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; OBESITY; TIME FACTORS; TRIGLYCERIDES;

EID: 41149120450     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.045     Document Type: Article

References (28)

1. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., and Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
2. Altmann S.W., Davis Jr. H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., and Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004) 1201-1204
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 (2002) 1221-1231
4. Anstee Q.M., and Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87 (2006) 1-16
5. Assy N., Grozovski M., Bersudsky I., Szvalb S., and Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J. Gastroenterol. 12 (2006) 4369-4376
6. Beltroy E.P., Liu B., Dietschy J.M., and Turley S.D. Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease. J. Lipid. Res. 48 (2007) 869-881
7. Carr T.P., Andresen C.J., and Rudel L.L. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26 (1993) 39-42
8. Cohen J.C., Pertsemlidis A., Fahmi S., Esmail S., Vega G.L., Grundy S.M., and Hobbs H.H. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1810-1815
9. Davies J.P., Scott C., Oishi K., Liapis A., and Ioannou Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280 (2005) 12710-12720
10. Davis Jr. H.R., Zhu L.J., Hoos L.M., Tetzloff G., Maguire M., Liu J., Yao X., Iyer S.P., Lam M.H., Lund E.G., Detmers P.A., Graziano M.P., and Altmann S.W. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279 (2004) 33586-33592
11. Devries-Seimon T., Li Y., Yao P.M., Stone E., Wang Y., Davis R.J., Flavell R., and Tabas I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell Biol. 171 (2005) 61-73
12. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
13. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis Jr. H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., Macintyre D.E., Ogawa A., O'Neill K., Iyer S.P., Shevell D.E., Smith M.M., Tang Y.S., Makarewicz A.M., Ujjainwalla F., Altmann S.W., Chapman K.T., and Thornberry N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8132-8137
14. Hughes E.A., Tracey I., Singhal S., and Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med. Hypotheses 67 (2006) 1463-1464
15. Ikejima K., Okumura K., Lang T., Honda H., Abe W., Yamashina S., Enomoto N., Takei Y., and Sato N. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol. Res. 33 (2005) 151-154
16. Jeong W.I., Jeong D.H., Do S.H., Kim Y.K., Park H.Y., Kwon O.D., Kim T.H., and Jeong K.S. Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J. Vet. Med. Sci. 67 (2005) 235-242
17. Kirsch R., Clarkson V., Shephard E.G., Marais D.A., Jaffer M.A., Woodburne V.E., Kirsch R.E., and Hall Pde L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18 (2003) 1272-1282
18. Lipka L.J. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc. Drug. Rev. 21 (2003) 293-312
19. Mari M., Caballero F., Colell A., Morales A., Caballeria J., Fernandez A., Enrich C., Fernandez-Checa J.C., and Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 4 (2006) 185-198
20. Mehta K., Van Thiel D.H., Shah N., and Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev. 60 (2002) 289-293
21. Park S.Y., Cho Y.R., Kim H.J., Higashimori T., Danton C., Lee M.K., Dey A., Rothermel B., Kim Y.B., Kalinowski A., Russell K.S., and Kim J.K. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 54 (2005) 3530-3540
22. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
23. Salen G., von Bergmann K., Lutjohann D., Kwiterovich P., Kane J., Patel S.B., Musliner T., Stein P., and Musser B. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109 (2004) 966-971
24. Telford D.E., Sutherland B.G., Edwards J.Y., Andrews J.D., Barrett P.H., and Huff M.W. The molecular mechanisms underlying the reduction of low density lipoprotein apoB-100 by ezetimibe plus simvastatin. J. Lipid. Res. 48 (2007) 699-708
25. Van Heek M., Compton D.S., France C.F., Tedesco R.P., Fawzi A.B., Graziano M.P., Sybertz E.J., Strader C.D., and Davis Jr. H.R. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. 99 (1997) 385-390
26. van Heek M., Austin T.M., Farley C., Cook J.A., Tetzloff G.G., and Davis H.R. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 50 (2001) 1330-1335
27. van Heek M., Compton D.S., and Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 415 (2001) 79-84
28. Wang D., Wei Y., and Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147 (2006) 943-951